Nitroxyl (HNO) for treatment of acute heart failure

Current Heart Failure Reports

Volumn 11, Issue 3, 2014, Pages 227-235

  Arcaro, Alessia ^a   Lembo, Giuseppe ^a,b   Tocchetti, Carlo G ^c  

^a IRCCS NEUROMED   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Clinica Montevergine   (Italy)

Author keywords

Cardiac function; Cardiomyocytes; Clinical studies; Experimental animal studies; Heart failure; Inotropic drugs; Nitroxyl; Reactive nitrogen species; Reactive oxygen species

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM ION; CARDIOVASCULAR AGENT; CXL 1020; CYCLIC AMP; CYCLIC GMP; INOTROPIC AGENT; NITRIC OXIDE DONOR; PHOSPHODIESTERASE INHIBITOR; TEMPOL; UNCLASSIFIED DRUG; ANTIOXIDANT; FREE RADICAL; NITROGEN OXIDE; NITROXYL;

ACUTE HEART FAILURE; CALCIUM HOMEOSTASIS; CELL LEVEL; EMBOLIZATION COIL; EXCITATION CONTRACTION COUPLING; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART STROKE VOLUME; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; IN VIVO STUDY; MYOFILAMENT; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC VASCULAR RESISTANCE; ANIMAL; DRUG EFFECTS; HEART CONTRACTION; HEART FAILURE; HEART MUSCLE; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY;

ANIMALS; ANTIOXIDANTS; FREE RADICALS; HEART FAILURE; HUMANS; MYOCARDIAL CONTRACTION; MYOCARDIUM; NITROGEN OXIDES; OXIDATIVE STRESS; STROKE VOLUME;

EID: 84906053204     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-014-0210-z     Document Type: Review

References (87)

1. Mudd JO, Kass DA. Tackling heart failure in the twenty-first century. Nature. 2008;451:919-28. (Pubitemid 351301747)
2. Fukuto JM, Jackson MI, Kaludercic N, Paolocci N. Examining nitroxyl in biological systems. Methods Enzymol. 2008;440:411-31.
3. Paolocci N, Wink DA. The shy Angeli and his elusive creature: the HNO route to vasodilation. Am J Physiol Heart Circ Physiol. 2009;296(5):H1217-20.
4. Paolocci N, Saavedra WF, Miranda KM, Martignani C, Isoda T, Hare JM, et al. Nitroxyl anion exerts redox-sensitive positive cardiac inotropy in vivo by calcitonin gene-related peptide signaling. Proc Natl Acad Sci U S A. 2001;98:10463-8. (Pubitemid 32803042)
5. Paolocci N, Katori T, Champion HC, St John ME, Miranda KM, Fukuto JM, et al. Positive inotropic and lusitropic effects of HNO/NO- in failing hearts: independence frombeta-adrenergic signaling. Proc Natl Acad Sci U S A. 2003;100:5537-42. (Pubitemid 36542740)
6. •• Sabbah HN, Tocchetti CG, Wang M, Daya S, Gupta RC, Tunin RS, et al. Nitroxyl (HNO): a novel approach for the acute treatment of heart failure. Circ Heart Fail. 2013;6:1250-8. The first cell-to-human proof of concept of the success of an HNO donor in improving inotropy in HF.
7. •• Tocchetti CG, Stanley BA, Murray CI, Sivakumaran V, Donzelli S, Mancardi D, et al. Playing with cardiac "redox switches": the "HNO way" to modulate cardiac function. Antioxid Redox Signal. 2011;14:1687-98. Comprehensive review on the biochemical modifications induced by HNO to improve contractility.
8. •• Gao WD, Murray CI, Tian Y, Zhong X, Dumond JF, Shen X, et al. Nitroxyl mediated disulfide bond formation between cardiac myofilament cysteines enhances contractile function. Circ Res. 2012;111:1002-11. Novel findings of HNO-induced redox modification of myofilaments to increase contractile force and Ca2+ sensitivity are reported.
9. •• Sivakumaran V, Stanley BA, Tocchetti CG, Ballin JD, Caceres V, Zhou L, et al. HNO enhances SERCA2a activity and cardiomyocyte function by promoting redox-dependent phospholamban oligomerization. Antioxid Redox Signal. 2013;19:1185-97. Very novel findings on PLN redox modifications induced by HNO to improve inotropy.
10. Fabiato A, Fabiato F. Calcium release from the sarcoplasmic reticulum. Circ Res. 1977;40(2):119-29. (Pubitemid 8043430)
11. Bers DM. Cardiac excitation-contraction coupling. Nature. 2002;415:198-205. (Pubitemid 34059525)
12. • Kranias EG, Hajjar RJ. Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res. 2012;110(12):1646-60. Recent and comprehensive paper on PLN and SERCA2a interactions in the modulation of myocardial contractility.
13. Gordon AM, Homsher E, Regnier M. Regulation of contraction in striated muscle. Physiol Rev. 2000;80(2):853-924. (Pubitemid 30164950)
14. • Solaro RJ, Kobayashi T. Protein phosphorylation and signal transduction in cardiac thin filaments. J Biol Chem. 2011;286(12):9935-40. The importance of phosphorylation of myofilament proteins to regulate myocardial function.
15. Bers DM. Altered cardiac myocyte Ca regulation in heart failure. Physiology (Bethesda). 2006;21:380-7. (Pubitemid 44879246)
16. Marx SO, Reiken S, Hisamatsu Y, Jayaraman T, Burkhoff D, Rosemblit N, et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell. 2000;101:365-76.
17. Curran J, Hinton MJ, Ríos E, Bers DM, Shannon TR. β-Adrenergic enhancement of sarcoplasmic reticulum calcium leak in cardiac myocytes is mediated by calcium/calmodulin-dependent protein kinase. Circ Res. 2007;100:391-8.
18. Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 2007;49:241-8. (Pubitemid 46142995)
19. • Nediani C, Raimondi L, Borchi E, Cerbai E. Nitric oxide/reactive oxygen species generation and nitroso/redox imbalance in heart failure: from molecular mechanisms to therapeutic implications. Antioxid Redox Signal. 2011;14:289-331. Interesting review on ROS and RNS balance in heart failure.
20. Tocchetti CG, Carpi A, Coppola C, Quintavalle C, Rea D, Campesan M, et al. Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. Eur J Heart Fail. 2014. doi:10.1002/ejhf.50 [Epub ahead of print].
21. Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohlmeyer TJ, Quaife RA, et al. Changes in gene expression in the intact human heart. Downregulation of α-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest. 1997;100:2315-24. (Pubitemid 27500155)
22. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005;111:2837-49. (Pubitemid 40791557)
23. Goldhaber JI, Hamilton MA. Role of inotropic agents in the treatment of heart failure. Circulation. 2010;121(14):1655-60.
24. • Hasenfuss G, Teerlink JR. Cardiac inotropes: current agents and future directions. Eur Heart J. 2011;32:1838-45. This paper highlights the importance of research in the field of inotropic treatments.
25. •• Tarone G, Balligand JL, Bauersachs J, Clerk A, De Windt L, Heymans S, et al. Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. Eur J Heart Fail. 2014;16(5):494-508. Very recent paper highlighting novel findings on alternative experimental therapeutics in HF.
26. Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation. 2006;113(2):305-15.
27. •• Nagy L, Pollesello P, Papp Z. Inotropes and inodilators for acute heart failure: sarcomere active drugs in focus. J Cardiovasc Pharmacol. 2014 May 1. [Epub ahead of print]. State-of-the-art review on Ca2+ sensitizers.
28. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006;8(1):105-10. (Pubitemid 43012109)
29. Cleland JG, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJ, Lang CC, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011;378:676-83.
30. • Malik FI, Hartman JJ, Elias KA,Morgan BP, Rodriguez H, Brejc K, et al. Cardiacmyosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011;331:1439-43. Very interesting findings on omecamtiv mecarbil, promising inotrope which activates cardiac myosin.
31. Gheorghiade M, Blair JE, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, et al. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol. 2008;51:2276-85.
32. • Jessup M, Greenberg B, Mancini D, Cappola T, Pauly DF, Jaski B, et al. Investigators CUbPAoGTiCDC. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure. Circulation. 2011;124:304-13. Data from the CUPID with SERCA2a gene transfer in HF are presented.
33. • Sikkel MB, Hayward C, MacLeod KT, Harding SE, Lyon AR. SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope. Br J Pharmacol. 2014;171(1):38-54. Promising results with SERCA2a gene transfer are described.
34. Miranda KM, Nagasawa HT, Toscano JP. Donors of HNO. Curr Top Med Chem. 2005;5:649-64. (Pubitemid 41179725)
35. • Guthrie DA, Kim NY, Siegler MA, Moore CD, Toscano JP. Development of N-substituted hydroxylamines as efficient nitroxyl (HNO) donors. J Am Chem Soc. 2012;134(4):1962-5. Development of new HNO donors.
36. Miranda KM, Dutton AS, Ridnour LA, Foreman CA, Ford E, Paolocci N, et al. Mechanism of aerobic decomposition of Angeli's salt (sodium trioxodinitrate) at physiological pH. J Am Chem Soc. 2005;127:722-31. (Pubitemid 40178747)
37. Miranda KM, Katori T, de Holding CLT, Thomas L, Ridnour LA, McLendon WJ, et al. Comparison of the NO and HNO donating properties of diazeniumdiolates: primary amine adducts release HNO in vivo. J Med Chem. 2005;48:8220-8. (Pubitemid 43032530)
38. Sha X, Isbell TS, Patel RP, Day CS, King SB. Hydrolysis of acyloxy nitroso compounds yields nitroxyl (HNO). J Am Chem Soc. 2006;128:9687-92. (Pubitemid 44147951)
39. Miller TW, Cherney MM, Lee AJ, Francoleon NE, Farmer PJ, King SB, et al. The effects of nitroxyl (HNO) on soluble guanylate cyclase activity: interactions at ferrous heme and cysteine thiols. J Biol Chem. 2009;284(33):21788-96.
40. Miranda KM, Nims RW, Thomas DD, Espey MG, Citrin D, Bartberger MD, et al. Comparison of the reactivity of nitric oxide and nitroxyl with heme proteins. A chemical discussion of the differential biological effects of these redox related products of NOS. J Inorg Biochem. 2003;93:52-60. (Pubitemid 36132133)
41. Ge Y, Moss RL. Nitroxyl, redox switches, cardiac myofilaments, and heart failure: a prequel to novel therapeutics? Circ Res. 2012;111(8):954-6.
42. Nagahara N, Matsumura T, Okamoto R, Kajihara Y. Protein cysteine modifications: (1) medical chemistry for proteomics. Curr Med Chem. 2009;16:4419-44.
43. .• Keceli G, Moore CD, Labonte JW, Toscano JP. NMR detection and study of hydrolysis of HNO-derived sulfinamides. Biochemistry. 2013;52(42):7387 -96. HNO biochemical reactions are described.
44. Kumar MR, Fukuto JM, Miranda KM, Farmer PJ. Reactions of HNO with heme proteins: new routes to HNO heme complexes and insight into physiological effects. Inorg Chem. 2010;49:6283-92.
45. • Nagahara N. Intermolecular disulfide bond to modulate protein function as a redox-sensing switch. Amino Acids. 2011;41:59-72. This manuscript highlights the importance of redox-switches and protein function modulation by redox modifications.
46. Zima AV, Blatter LA. Redox regulation of cardiac calcium channels and transporters. Cardiovasc Res. 2006;71(2):310-21.
47. • Köhler AC, Sag CM, Maier LS. Reactive oxygen species and excitation-contraction coupling in the context of cardiac pathology. J Mol Cell Cardiol. 2014 Mar 11. Very novel and comprehensive manuscript on EC-coupling and ROS.
48. Wouters MA, Fan SW, Haworth NL. Disulfides as redox switches: from molecular mechanisms to functional significance. Antioxid Redox Signal. 2010;12:53-91.
49. Zhang GX, Kimura S, Nishiyama A, Shokoji T, Rahman M, Yao L, et al. Cardiac oxidative stress in acute and chronic isoproterenol-infused rats. Cardiovasc Res. 2005;65:230-8. (Pubitemid 40038496)
50. Meissner G. Regulation of ryanodine receptor ion channels through posttranslationalmodifications. Current topics in membranes, edited by Serysheva, I. Burlington: Academic Press. 2010;66:91-113.
51. Pessah IN, Feng W. Functional role of hyperreactive sulfhydryl moieties within the ryanodine receptor complex. Antioxid Redox Signal. 2000;2:17-25. (Pubitemid 30202449)
52. Canton M, Neverova I, Menabò R, Van Eyk J, Di Lisa F. Evidence of myofibrillar protein oxidation induced by postischemic reperfusion in isolated rat hearts. Am J Physiol Heart Circ Physiol. 2004;286(3):H870-7. (Pubitemid 38248597)
53. Canton M, Skyschally A, Menabo R, Boengler K, Gres P, Schulz R, et al. Oxidative modification of tropomyosin and myocardial dysfunction following coronary microembolization. Eur Heart J. 2006;27:875-81.
54. Terentyev D, Gyorke I, Belevych AE, Terentyeva R, Sridhar A, Nishijima Y, et al. Redox modification of ryanodine receptors contributes to sarcoplasmic reticulum Ca2+ leak in chronic heart failure. Circ Res. 2008;103:1466-72.
55. Hertelendi Z, Toth A, Borbely A, Galajda Z, van der Velden J, Stienen GJ, et al. Oxidation of myofilament protein sulfhydryl groups reduces the contractile force and its Ca2+ sensitivity in human cardiomyocytes. Antioxid Redox Signal. 2008;10:1175-84. (Pubitemid 351620310)
56. Hool LC. The L-type Ca(2+) channel as a potential mediator of pathology during alterations in cellular redox state. Heart Lung Circ. 2009;18:3-10.
57. Tocchetti CG, Wang W, Froehlich JP, Huke S, Aon MA, Wilson GM, et al. Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulum Ca2+ cycling. Circ Res. 2007;100:96-104. (Pubitemid 46066777)
58. Kohr MJ, Kaludercic N, Tocchetti CG, Dong GW, Kass DA, Janssen PM, et al. Nitroxyl enhances myocyte Ca2 + transients by exclusively targeting SR Ca2 +-cycling. Front Biosci (Elite Ed). 2010;2:614-26.
59. + release from skeletal and cardiac sarcoplasmic reticulum by oxidizing ryanodine receptors. Cell Calcium. 2005;37:87-96.
60. Lancel S, Zhang J, Evangelista A, Trucillo MP, Tong XY, Siwik DA, et al. Nitroxyl activates SERCA in cardiac myocytes via glutathiolation of cysteine 674. Circ Res. 2009;104:720-3.
61. Froehlich JP, Mahaney JE, Keceli G, Pavlos CM, Goldstein R, Redwood AJ, et al. Phospholamban thiols play a central role in activation of the cardiac muscle sarcoplasmic reticulum calcium pump by nitroxyl. Biochemistry. 2008;47:13150-2.
62. Negash S, Chen LT, Bigelo.w DJ, Squier TC. Phosphorylation of phospholamban by cAMP-dependent protein kinase enhances interactions between Ca-ATPase polypeptide chains in cardiac sarcoplasmic reticulum membranes. Biochemistry. 1996;35:11247-59. (Pubitemid 26299297)
63. Dai T, Tian Y, Tocchetti CG, Katori T, Murphy AM, Kass DA, et al. Nitroxyl increases force development in rat cardiac muscle. J Physiol. 2007;580:951-60. (Pubitemid 46909044)
64. Yong QC, Hu LF, Wang S, Huang D, Bian JS. Hydrogen sulfide interacts with nitric oxide in the heart: possible involvement of nitroxyl. Cardiovasc Res. 2010;88:482-91.
65. El-Armouche A, Wahab A, Wittkopper K, Schulze T, Bottcher F, Pohlmann L, et al. The new HNO donor, 1-nitrosocyclohexyl acetate, increases contractile force in normal and betaadrenergically desensitized ventricular myocytes. Biochem Biophys Res Commun. 2010;402:340-4.
66. • Zhang Y, Tocchetti CG, Krieg T, Moens AL. Oxidative and nitrosative stress in the maintenance of myocardial function. Free Radic Biol Med. 2012;53(8):1531-40. This manuscript highlights the importance of the nitroso-redox balance in modulating myocardial function.
67. Massion PB, Pelat M, Belge C, Balligand JL. Regulation of the mammalian heart function by nitric oxide. Comp Biochem Physiol A Mol Integr Physiol. 2005;142:144-50. (Pubitemid 41443574)
68. Katori T, Donzelli S, Tocchetti CG, Miranda KM, Cormaci G, Thomas DD, et al. Peroxynitrite and myocardial contractility: in vivo versus in vitro effects. Free Radic Biol Med. 2006;41:1606-18. (Pubitemid 44550084)
69. Paolocci N, Jackson MI, Lopez BE, Miranda K, Tocchetti CG, Wink DA, et al. The pharmacology of nitroxyl (HNO) and its therapeutic potential: not just the Janus face of NO. Pharmacol Ther. 2007;113:442-58.
70. Katori T, Hoover DB, Ardell JL, Helm RH, Belardi DF, Tocchetti CG, et al. Calcitonin gene-related peptide in vivo positive inotropy is attributable to regional sympatho-stimulation and is blunted in congestive heart failure. Circ Res. 2005;96:234-43. (Pubitemid 40209371)
71. Favaloro JL, Kemp-Harper BK. The nitroxyl anion (HNO) is a potent dilator of rat coronary vasculature. Cardiovasc Res. 2007;73(3):587-96. (Pubitemid 46073951)
72. Andrews KL, Irvine JC, Tare M, Apostolopoulos J, Favaloro JL, Triggle CR, et al. A role for nitroxyl (HNO) as an endothelium-derived relaxing and hyperpolarizing factor in resistance arteries. Br J Pharmacol. 2009;157(4):540-50.
73. Fukuto JM, Chiang K, Hszieh R, Wong P, Chaudhuri G. The pharmacological activity of nitroxyl: a potent vasodilator with activity similar to nitric oxide and/or endothelium derived relaxing factor. J Pharmacol Exp Ther. 1992;263:546-51.
74. Bermejo E, Sáenz DA, Alberto F, Rosenstein RE, Bari SE, Lazzari MA. Effect of nitroxyl on human platelets function. Thromb Haemost. 2005;94(3):578-84. (Pubitemid 41300855)
75. Tsihlis ND, Murar J, Kapadia MR, Ahanchi SS, Oustwani CS, Saavedra JE, et al. Isopropylamine NONOate (IPA/NO) moderates neointimal hyperplasia following vascular injury. J Vasc Surg. 2010;51(5):1248-59.
76. Zgheib C, Sebastian T, Tocchetti CG, Paolocci N, King SB, Kurdi M, et al. Nitroxyl activates redox-sensitive stress signaling in endothelial cells and has anti-inflammatory actions. Hypertension. 2010;56:e128.
77. • Bullen ML,Miller AA, Andrews KL, Irvine JC, Ritchie RH, Sobey CG, et al. Nitroxyl (HNO) as a vasoprotective signaling molecule. Antioxid Redox Signal. 2011;14:1675-86. This manuscript highlights the importance of HNO in the vasculature.
78. • Burgoyne JR, Mongue-Din H, Eaton P, Shah AM. Redox signaling in cardiac physiology and pathology. Circ Res. 2012;111:1091-106. This paper describes the role of redox balance in the regulation of cardiac function.
79. Irvine JC, Gossain S, Love JE, Kaye DM, Kemp-Harper BK, Ritchie RH. The protective role of nitroxyl (HNO) against cardiomyocytes hypertrophy via cGMP signaling. Hypertension. 2009;53:1109.
80. • Bullen ML, Miller AA, Dharmarajah J, Drummond GR, Sobey CG, Kemp-Harper BK. Vasorelaxant and antiaggregatory actions of the nitroxyl donor isopropylamine NONOate are maintained in hypercholesterolemia. Am J Physiol Heart Circ Physiol. 2011;301(4):H1405-14. Important data showing how HNOeffects are preserved in diseased vessels.
81. Colucci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 1. N Engl J Med. 1986;314:290-9. (Pubitemid 16146603)
82. Colucci WS, Wright RF, Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2. N Engl J Med. 1986;314:349-58. (Pubitemid 16166262)
83. Fonarow GC. Role of carvedilol controlled-release in cardiovascular disease. Expert Rev Cardiovasc Ther. 2009;7:483-98.
84. Pagliaro P, Mancardi D, Rastaldo R, Penna C, Gattullo D, Miranda KM, et al. Nitroxyl affords thiol-sensitive myocardial protective effects akin to early preconditioning. Free Radic Biol Med. 2003;34(1):33-43. (Pubitemid 36043884)
85. • Queliconi BB, Wojtovich AP, Nadtochiy SM, Kowaltowski AJ, Brookes PS. Redox regulation of the mitochondrial K(ATP) channel in cardioprotection. Biochim Biophys Acta. 2011;1813(7):1309-15. Redox regulation and cardioprotection.
86. Hewett SJ, Espey MG, Uliasz TF, Wink DA. Neurotoxicity of nitroxyl: insights into HNO and NO biochemical imbalance. Free Radic Biol Med. 2005;39(11):1478-88. (Pubitemid 41547228)
87. Choe CU, Lewerenz J, Fischer G, Uliasz TF, Espey MG, Hummel FC, et al. Nitroxyl exacerbates ischemic cerebral injury and oxidative neurotoxicity. J Neurochem. 2009;110(6):1766-73.